Funding (Updated 09/12/2014)

Funding (Updated 09/12/2014)

Find information below about:

  • External Funding Opportunities
  • Internal Funding Opportunties
External Funding Opportunities​​

Gut-Microbiome-Brain Interactions and Mental Health 
     R21/R33     RFA-MH-15-850     Phased Innovation Award

This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations to investigate mechanisms by which the gut microbiome modulates the development and function of brain circuits that subserve behavioral functions of direct relevance to the mission of the NIMH.  Because initial colonization of the gut by microbiota occurs early in life and may influence the subsequent development and modifiability of the central nervous system, developmental studies are of interest. Applicants may propose to use wild-type, gnotobiotic, and/or specific pathogen-free model organisms. With this FOA, the NIMH encourages investigator teams to initiate hypothesis-driven research in this cross-cutting research area and to identify promising mechanistic leads for future basic and translational research that will advance the mission of the NIMH. 

    Letter of Intent Due Date: October 25, 2014
    Application Due Date: 5pm, November 25, 2014

Epigenetic Analyses of Aging as a Risk Factor for Multiple Chronic Conditions 
     U34     RFA-AG-15-004

The emergent field of geroscience seeks to relate the biology of aging to the development of chronic diseases and the onset of degenerative conditions which are prevalent in the older segment of human populations. It is generally accepted that age is the major risk factor for most chronic diseases and degenerative conditions in adults. Thus, a critical question in geroscience is to identify components in the biology of aging that are the underlying risk for multiple chronic diseases and degenerative conditions. Therefore, this FOA will support planning grants to circumscribe the scope of this question and suggest ways to answer it experimentally. The focus will be on epigenetics underlying aging as a risk factor for age-related diseases and degenerative conditions in humans. Mortality and age-related mortality are outside the scope of this FOA. Studies using model organisms are outside the scope of this FOA.

    Letter of Intent Due Date: December 15, 2014
    Application Due Date: 5pm, January 15, 2015

Advancing Interventions to Improve Medication Adherence 
     R21 PA-14-335
     R01 PA-14-334​

This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered. 

    Letter of Intent Due Date: None
    Application Due Date: Standard NIH Deadlines (until 01/08/2018)

Comparative Health System Performance in Accelerating PCOR Dissemination (U19)

As part of AHRQ's PCOR dissemination efforts, this AHRQ Funding Opportunity Announcement (FOA) invites applications for Centers of Excellence to identify, classify, track, and compare healthcare delivery systems ranging from integrated delivery systems to Accountable Care Organizations across the U.S. to help improve the speed of adoption and diffusion of CER-recommended practices through systems.

    Letter of Intent Due Date: September 5, 2014
    Application Due Date: October 17, 2014

NSF Computer Systems Research (CSR) Program​
Computer and Network Systems (CNS): Core Programs (RFA)
  • Computer Systems Research (CSR): Core Area and Highlighted Areas
  • Networking Technology and Systems (NeTS) : Core Area and Highlighted Areas
Information and Intelligent Systems (IIS): Core Programs (RFA
  •      Cyber-Human Systems (CHS)
  •      Information Integration & Informatics (III) (RFA2)
  •      Robust Intelligence (RI)
Computing and Communication Foundations (CCF): Core Programs (RFA)
  •      Algorithmic Foundations (AF)
  •      Communications and Information Foundations (CIF)
  •      Software and Hardware Foundations (SHF)
The Computer Systems Research (CSR) program supports transformative research in computer systems including:  multi-core architectures, operating systems, middleware and run-time support systems, programming models and tools, storage and file systems, hybrid and embedded systems, web-based systems, datacenters, distributed systems, parallel systems, large scale grids, wireless systems, mobile systems, and sensor systems. 

    Letter of Intent Due Date: None
    Application Due Date: See RFA

Research Planning Infrastructure to Develop Therapeutic Target-ID Strategies Based on Favorable Genetic Variants of Human Longevity or Health Span (U24) 


This FOA invites applications for a project for the development of a research planning infrastructure by a multidisciplinary collaborative team to develop target identification (ID) strategies based on effects of genetic factors reliably associated with increased human lifespan and/or health span. The phrase "target ID strategy" refers to a concerted set of applied research approaches (e.g., additional analyses, conducting required types of studies/ experiments and methodologies in the appropriate sequence) leading to the identification of genetic factors, pathways, or molecules by which activities could be favorably modified. Planning activities to be conducted by the U24 project include the creation of an integrated database of relevant data, informatics and computational tools for assessing the effects of favorable gene variants, evaluating their potential utility for developing therapeutic ID strategies, developing plans for experiments and analyses aimed at identifying one or more therapeutic target(s) and establishing a publicly available resource. Core areas of expertise which should be represented in the U24 multidisciplinary team include genetics, genomics, epidemiology, aging research, translational genomics, drug development, statistics, and bioinformatics. 

    Letter of Intent Due Date: October 6, 2014
    Application Due Date: November 6, 2014 by 5PM CT

Bioreactors for Reparative Medicine 
     R41/R42     RFA-HL-15-004
     R43/R44     RFA-HL-15-008  
     R44            RFA-HL-15-017

Major obstacles to the generation of functional tissues and their widespread use are limited by rudimentary tissue growth technologies. The purpose of this funding opportunity is to encourage small businesses to develop sophisticated and complex biomimetic culture systems that are capable of precise control of the cellular and 3-dimensional organ microenvironment, and which address the unique physiological dynamics of heart, lung and blood tissues.  Projects awarded under this announcement should show evidence of developing or using good laboratory practice (GLP) standards and/or good manufacturing practices (GMP) standards, which play an important role in the adoption of many technologies used for pre-clinical research.  Additionally, sources of cell variability should be discussed in the context of potential elements of measurement assurance and use of reference materials.  For projects proposing clinical grade bioreactors and clinical investigations, an applicant must provide evidence that they have contacted the Food and Drug Administration (FDA) for guidance concerning the development of their bioreactor device, such as correspondence regarding Investigational New Drug (IND) Application and status of their project in a timeline related to Federal regulatory approval processes. 

    Letter of Intent Due Date: 30 days before deadline
    Application Due Date: October 10 or April 14 by 5pm
                                           (until 04/15/2016) CT

Platform Delivery Technologies for Nucleic Acid Therapeutics 
     R43/R44 PA-14-307
     R41/R42 PA-14-308

The purpose of this initiative is to incentivize small businesses to generate new technologies and products for  delivering nucleic acids  into cells and tissues for the purpose of treatment or prevention of human disease.   

    Letter of Intent Due Date: None
    Application Due Date: Standard deadlines (until September 8, 2016)​

Testing Interventions for Health-Enhancing Physical Activity 
     R01; PAR-14-315
The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level intervention programs of 1 to 2 years in length that are designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation.  This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.  

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until September 8, 2017)

Developing Interventions for Health-Enhancing Physical Activity 
      R21/R33; PAR-14-321

This Funding Opportunity Announcement (FOA) encourages applications for Phased Innovation (R21/R33) grant awards to support highly innovative research aimed at developing multi-level interventions that will increase health-enhancing physical activity: 1) in persons or groups who can benefit from such activity; and 2) that can be made scalable and sustainable for broad use across the nation.  This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase). Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds.  

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until September 8, 2017)

Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care 
     R01 PA-14-312
     R03 PA-14-313
     R21 PA-14-311​

This funding opportunity announcement (FOA) encourages a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.     

    Letter of Intent Due Date: 30 days before the deadline
    Application Due Date: Standard dates apply (until September 8, 2017)


Translational and Clinical Studies to Inform Final Device Design 
  PAR-14-300  U44 SBIR Cooperative Agreement – Fast-Track
  PAR-14-297  UH2/UH3 Phase Innovation Awards Cooperative Agreement

Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE)  
  PAR-14-298  UH2/UH3 Phase Innovation Awards Cooperative Agreement
  PAR-14-299​  U44 SBIR Cooperative Agreement – Fast-Track

Translational and Clinical Studies on the Path to 510(k) 
  PAR-14-296  U44  SBIR Cooperative Agreement – Fast-Track
  PAR-14-295​  UH2/UH3 Phase Innovation Awards Cooperative Agreement

The purpose of these Funding Opportunity Announcements (FOA) is to encourage applications to pursue translational and Early Feasibility Studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE), with the option of also supporting the following Early Feasibility Study.   It is expected the immediate next steps upon completion of the Early Feasibility Study will be a full Feasibility Study and a Pivotal Trial in support of a PMA (Pre-Market Approval) or HDE (Humanitarian Device Exemption). Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and an Early Feasibility Study.   

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until May 8, 2017)

Scientific/Research Contact:​

NIH Transformative Research Awards (R01)

The NIH Transformative Research Awards complement NIH’s traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research. 

    Letter of Intent Due Date: September 10, 2014
    Application Due Date: October 10, 2014, 5pm CT (including AIDS apps)

AHRQ Health Services Researc
    Demonstration and Dissemination Grants   R18    PA-14-290  
    Research Projects   R01    PA-14-291​  

The Research Demonstration and Dissemination Grant (R18) is an award made by AHRQ to an institution/organization to support a discrete, specified health services research project. The project will be performed by the named investigator and study team. The R18 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard dates apply 
       (until May 26, 2017 for R18; until July 6, 2017 for R01)

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System 

    UH2/UH3 (SBIR/STTR)   PAR-14-293  
    U44 (Cooperative Agreement)  PAR-14-292

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.  

    Letter of Intent Due Date: 30 days before deadline
    Application Due Date: See RFA (until May 8, 2017)

2015 PhRMA Research and Training Awards 

Health Outcomes Application Deadline : 02-01-2015
Clinical Pharmacology Application Deadline : 02-01-2015 Translational Medicine and Therapeutics Application Deadline : 02-01-2015

The PhRMA Foundation funds scientists at critical points in their research careers to support and reward innovation in disciplines essential to the development of safe and effective medicines. The PhRMA Foundation offers competitive pre and post doctoral fellowships, sabbatical fellowships, and research starter grants to advance science in Adherence Improvement, Clinical Pharmacology, Comparative Effectiveness Research, Health Outcomes, Informatics, Pharmaceutics, Pharmacology/Toxicology, and Translational Medicine and Therapeutics.

High Throughput Screening (HTS) to Discover Chemical Probes

     PAR-14-283       R21
     PAR-13-134      X01 
     PAR-13-135      R03
     PAR-14-284      R01 

These Funding Opportunity Announcements (FOAs) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to deadline
    Application Due Date: Standard dates apply (until 09/08/17)​

Pilot Centers for Precision Disease Modeling (U54)

This Funding Opportunity Announcement (FOA) invites U54 cooperative agreement applications for Pilot Centers for Precision Disease Modeling. The goal of the Centers is to support collaborative research projects that link current personalized medicine efforts in human subjects with advances in animal genomics and technologies for genetic manipulation and creation of interspecies somatic hybrids. Functionally linking these areas of research will produce programs to enhance the predictive value of pre-clinical studies based on the use of precision animal models. Centers will establish demonstration pipelines for pre-clinical scientific discovery, disease modeling, and development of interventions based on innovative animal models. These preclinical pipelines eventually will be an integral part of diagnostics, care and therapeutic treatment of patients. Each Center should have a set of required components: a Coordination Section to assure effective multidisciplinary leadership; a Pre-clinical/Co-clinical Section to collect and distribute patient information; a Bioinformatics Section to provide diverse computational abilities; and, as a major emphasis, a Disease Modeling Unit for the creation and testing of at least three precision animal projects. Even though the centers will work on a limited number of focused projects, it is expected that the program will maintain multifaceted research activities to build core model systems that can be adjusted as required to accommodate a broad spectrum of diseases.  

    Letter of Intent Due Date: Not applicable
    Application Due Date: October 1, 2014, 5pm CT 

Ethical, Legal, and Social Implications (ELSI) of Genomic Research
    Exploratory/Developmental Research Program (R21)  PA-14-278    
    Regular Research Program (R01)    PA-14-276
    Small Research Grant Program (R03)    PA-14-277    

This Funding Opportunity Announcement (FOA) invites Exploratory / Developmental Research Program Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications should propose exploratory or developmental studies that break new ground or extend previous discoveries in new directions.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard NIH deadlines apply (until 09/08/17) 

Discovery of in vivo Chemical Probes (R01)

This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to due date
    Application Due Date: Standard NIH deadlines apply (until 09/07/17) 

Career Awards for Medical Scientists (Burroughs Wellcome Fund)

The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research.  Proposals in health services research or involving large-scale clinical trials are not eligible.

    INTERNAL UAB DEADLINE: August 10, 2014, 5pm CT
        Please see left column for guidance on limited institutional submissions
    Application Due Date: October 1, 2014, 3pm CT

 Investigators in the Pathogenesis of Infectious Disease (Burroughs Wellcome Fund)

This award provides $500,000 over a period of five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters. The awards are intended to give recipients the freedom and flexibility to pursue new avenues of inquiry and higher-risk research projects that hold potential for significantly advancing the biochemical, pharmacological, immunological, and molecular biological understanding of how microbes and the human body interact.

    INTERNAL UAB DEADLINE: September 10, 2014, 5pm CT
        Please see left column for guidance on limited institutional submissions
     Application Due Date: November 3, 2014, 3pm CT

Comparative Health System Performance in Accelerating PCOR Dissemination (U19)

As part of AHRQ's PCOR dissemination efforts, this AHRQ Funding Opportunity Announcement (FOA) invites applications for Centers of Excellence to identify, classify, track, and compare healthcare delivery systems ranging from integrated delivery systems to Accountable Care Organizations across the U.S. to help improve the speed of adoption and diffusion of CER-recommended practices through systems. 

    Letter of Intent Due DateSeptember 5, 2014
    Application Due Date: October 17, 2014 by 5PM CT

Development of Novel Therapeutics for Select Pathogens (R21/R33) 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support basic to translational research focused on development of novel therapeutics against select antibiotic-resistant gram-negative bacteria or influenza. 

    Letter of Intent Due DateSeptember 19, 2014  
    Application Due Date: October 20, 2014, by 5:00 PM 

DoD Spinal Cord Injury Translational Research Award

The SCIRP Translational Research Award mechanism was first offered in FY12. Since then, 21 Translational Research Award applications have been received, and 4 have been recommended for funding. The SCIRP Translational Research Award is intended to support translational research that will accelerate the movement of promising ideas in spinal cord injury research into clinical applications. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. While the ultimate goal of translational research is to move an observation forward into clinical application, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. Developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism may be found at Applications must include preliminary and/or published data that is relevant to SCI and the proposed research project. Optional Qualified Collaborator: The FY14 SCIRP strongly encourages multidisciplinary collaborations among academic scientists and clinicians, industry scientists, the military Services, the VA, and other federal Government agencies. Collaborations with early-career investigators in the SCI field are encouraged. Although more than one collaborator may participate in the application, only one may be named for this option. The PI must submit a Statement of Collaboration that clearly identifies the collaborating investigator and addresses how each of the criteria listed below are met. Additionally, the collaborator must provide a biographical sketch (see Section II.C.3, Research and Related Senior/Key Person Profile) and a letter of collaboration (see Section II.C.2, Attachment 9: Statement of Collaboration) describing his/her involvement in the proposed research project.  It should be clear that the success of the proposed research project depends on the complementary skills and contributions of both the PI and collaborator.  The collaborator must significantly contribute to the proposed research project such that it could not be accomplished without his/her involvement. ○ A proposed research project in which the collaborator merely supplies tissue samples or access to patients will not meet the intent and will not be qualified for the higher level of funding. ○ At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the application’s budget.  The collaborator must be in a position with freedom to pursue independent research goals without formal mentorship.

    Letter of Intent Due Date: Not applicable
    Application Due Date: Oct 30, 2014 

Translational Research to Help Older Adults Maintain their Health and Independence in the Community

R21: PA-14-159 (link)

R01: PA-14-161 (link)

This Funding Opportunity Announcement (FOA) invites applications using the R01 award mechanism for translational research that moves evidence-based research findings toward the development of new interventions, programs, policies, practices, and tools that can be used by organizations in the community to help older adults remain healthy and independent, productively engaged, and living in their own homes and communities.  The goal of this FOA is to support translational research involving collaborations between academic research centers and community-based organizations with expertise serving or engaging older adults (such as city and state health departments, city/town leadership councils, educational institutions, workplaces, Area Agencies on Aging, and organizations funded or assisted by the Corporation for National and Community Service) that will enhance our understanding of practical tools, techniques, programs and policies that communities across the nation can use to more effectively respond to needs of the aging population. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard dates by 5PM CT (until May 8, 2017)

Biomedical Technology Research Resource (P41)
   PAR-14-023      Pre-Application
   PAR-14-021​   Full Proposal

This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources. These Resources conduct research and development on new technologies and new/improved instruments driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available, to train members of the research community in the use of the technologies, and to disseminate these technologies and the Resource’s experimental results broadly. New applicants are strongly encouraged to submit a pre-application to PAR-14-023. The pre-application process provides feedback regarding the appropriateness for this program and competitiveness of a potential application.

    Letter of Intent Due Date: Not applicable
    Application Due Date: Sep 25, 2014; Jan 25, 2015; May 25, 2015; 
    Sep 25, 2015; Jan 25, 2016; May 25, 2016; Sep  25, 2016, by 5:00 PM​

Assessment of Prevention, Diagnosis, and Treatment Options – Fall 2014 Cycle

PCORI is seeking applications for comparative effectiveness research designed to provide information that would inform critical decisions that face patients and caregivers, clinicians, policy makers, and health care system leaders. These decisions must be consequential and be occurring now in the absence of sound evidence about the comparative effectiveness of alternative approaches. There must be substantial potential that patients/caregivers will benefit from the new knowledge in ways that are important to them. The premise of this research is that the new knowledge will inform critical choices by patients and stakeholders in health care. This knowledge will provide insight about the comparative benefits and harms of the options and provide information about outcomes that are important to patients.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Improving Healthcare Systems – Fall 2014 Cycle

PCORI is seeking applications to study the comparative effectiveness of alternate features of healthcare systems (e.g., innovative technologies, personnel deployments, incentives, service designs) designed to optimize the quality, outcomes, and/or efficiency of care for the patients they serve. Healthcare systems include private and public health insurance plans; physician groups; hospitals, nursing homes and assisted living facilities; academic medical centers; integrated delivery systems; community-based and safety-net clinics; federal, state, and municipal providers; and other entities organized to deliver, arrange, purchase, or coordinate healthcare services. PCORI seeks studies that will provide information of value to patients, their caregivers, and clinicians, as well as to healthcare leaders, regarding which features of systems lead to better patient-centered outcomes. 

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Communication and Dissemination Research – Fall 2014 Cycle

PCORI seeks to fund projects that address critical knowledge gaps in the communication and dissemination process—both the communication and dissemination of research results to patients, their caregivers, and clinicians, as well as the communication between patients, caregivers, and clinicians in the service of enabling patients and caregivers to make the best possible decisions in choosing among available options for care and treatment.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Addressing Disparities – Fall 2014 Cycle

In this PCORI Funding Announcement (PFA), we seek to fund comparative effectiveness research (CER) studies that evaluate and compare new and/or enhanced interventions to reduce or eliminate disparities in health and health care. Studies in the Addressing Disparities program should focus on overcoming barriers that may disproportionately affect the outcomes of specific groups of patients, or identify best practices for sharing results and information about patient-centered research across patient groups.
    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Improving Methods for Conducting Patient-Centered Outcomes Research – Fall 2014 Cycle

In this PCORI Funding Announcement (PFA), we seek projects to address gaps in methodological research relevant to conducting patient-centered outcomes research (PCOR). Results of these projects will inform future iterations of PCORI’s Methodology Report. The improvement of existing methods will benefit all stakeholders, including researchers planning investigations, policy makers weighing the value of healthcare interventions, and patients, clinicians, and caregivers facing healthcare decisions.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Partnerships for Innovation: Accelerating Innovation Research- Technology Translation

The NSF Partnerships for Innovation (PFI) program within the Division of Industrial Innovation and Partnerships (IIP) is an umbrella for two complementary subprograms, Accelerating Innovation Research (AIR) and Building Innovation Capacity (BIC). Overall, the PFI program offers opportunities to connect new knowledge to societal benefit through translational research efforts and/or partnerships that encourage, enhance and accelerate innovation and entrepreneurship. The subject of this solicitation is PFI: AIR-Technology Translation (PFI: AIR-TT). The PFI: AIR-TT solicitation serves as an early opportunity to move previously NSF-funded research results with promising commercial potential along the path toward commercialization. Projects are supported to demonstrate proof-of-concept, prototype, or scale-up while engaging faculty and students in entrepreneurial/innovative thinking. WEBINAR: A webinar will be held within 6 weeks of the release date of this solicitation to answer any questions about this solicitation. Details will be posted on the IIP website ( as they become available.

    Letter of Intent Due Date: September 02, 2014, March 13, 2015
    Application Due Date: 5PM CT, October 02, 2014, April 14, 2015

Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care SBIR 

R43/R44 RFA-HL-14-011

The purpose of this Funding Opportunity Announcement (FOA) is to support research using advanced technologies to develop novel point-of-care (POC) devices and implement existing technologies in clinical settings with a goal to guide diagnostic and therapeutic efforts for the heart, lung, blood (HLB) and sleep disorders. 

R43/R44 and R41/R42:   Budget: Budgets up to $225,000 total costs for Phase I and up to $1,500,000 total costs for Phase II may be requested. 

    Letter of Intent Due Date(s)
     R43/R44 Sept.15, 2014; March 16, 2015; Sept. 15, 2015 
     R41/R42 Not applicable

     Application Deadline(s)
     ​R43/R44 Oct.15, 2014; April 16, 2015; Oct.15, 2015;by 5PM
     R41/R42 Oct. 15, 2014; Oct.15, 2015, Oct.15, 2016, by 5PM

Alabama Launchpad Small Business Innovation Research(SBIR) and the Small Business Technology Transfer Programs

Administered by the US Small Business Administration, through which many of the largest federal agencies award contracts and grants to small businesses.  The purpose of the Alabama SBIR/STTR Support Program is to increase the success rate and competitiveness of SBIR/STTR applicants in the state. The program will provide support in three ways:

  1. Raise SBIR/STTR awareness for Alabama-based small businesses through a statewide network of partners that will advocate and host introductory SBIR/STTR workshops

  2. Educate Alabama companies on how to compete for SBIR/STTR awards

  3. Provide one-on-one writing assistance and proposal strategy from an expert with decades of experience writing and reviewing SBIR/STTR proposals


  • Beyond-the-basics training about SBIR and STTR Programs

  • How to prepare competitive proposals and proposal strategy

  • Avoiding common proposal mistakes

  • Federal agency focused workshops

  • Proposal evaluation

  • Individual writing assistance

Applicants can receive extensive proposal writing assistance for a chance to receive over $1 million in SBIR/STTR funding. Click here for more info.

Sponsor: Alabama SBIR/STTR Support Program

Letter of Intent: None

Application Deadline: Rolling


Community Partnerships to Advance Research (CPAR)

R21: PA-14-141,  Exploratory/Developmental Grant

R01: PA-14-142,  Research Project Grant   

R15: PA-14-140,  Academic Research Enhancement Award (AREA)

This funding opportunity announcement (FOA) encourages researchers to partner with communities using Community Engaged Research (CEnR) methodologies that will enhance relationships leading to better interventions and positive health outcomes.     Research objectives aim to partner with a community entity on health issues that is of mutual concern, such as but not limited to:

  • Interventions/programs for health promotion/prevention
  • Interventions/programs leading to self-management in chronic conditions
  • Programs that target self or symptom management
  • Examine ways to enhance or implement sustainable health programs in community settings  

Sponsor: NIH

Letter of Intent: None

Application Deadline: Standard NIH Dates Apply (until May 8, 2017)

Large Pragmatic Studies to Evaluate Patient-Centered Outcomes – Fall 2014 Cycle

PCORI is now accepting Letters of Intent (LOIs) through our second call for proposals to conduct large pragmatic clinical studies. We'll provide up to $90 million to fund approximately nine such studies, which are designed to address important questions faced by typical patients and clinicians. 

Patient-Centered Outcomes Research Institute (PCORI) seeks to fund pragmatic clinical trials (PCTs), large simple trials (LSTs), or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving health care system–level approaches to managing care; or for eliminating health or healthcare disparities.  Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, and/or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.  For this solicitation, PCORI is requiring that relevant patient organizations, professional organizations, and/or payer or purchaser organizations be included as partners and actively participate in the study. PCORI expects that most awards will be made for study designs that use randomization, either of individual participants or clusters, to avoid confounding bias. However, we recognize that exceptional opportunities may arise, by virtue of natural experiments and/or the existence of large registries, to address pragmatic questions using observational designs. This new PCORI program will not support applications to conduct cost-effectiveness analysis, evidence synthesis, or to study decision-support tools. 

    Letter of Intent Due Date: June 27, 2014 at 5:00 p.m. (ET)
    Invited Application Due Date: November 4, 2014, by 5:00 p.m. (ET)

Translational Programs in Lung Diseases (P01)

This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications from institutions/organizations that will perform collaborative, translational research with the goal of using mechanistic research as the basis for the rational design of clinical applications to improve prevention, diagnosis and/or treatment of lung diseases and sleep disorders. 

Award Budget: Less than $1.75 million per year direct costs (exclusive of F&A costs associated with consortia) for a maximum of $8.75 million directs costs over a five-year project period.

Letter of Intent Due Date: 30 days prior to the application due date
Application Due Date: 5pm CT - September 22, 2014; May 19, 2015; September 22, 2015; May 19, 2016; September 22, 2016; May 19, 2017

Grants to Enhance Applicability of Mouse Models for Translational & Oncologic Research

PAR-14-241 R01 Research Projects to Enhance Applicability of Mouse Models for Translational Research
PAR-14-240 R01 Research Project Grant
PAR-14-239 ​U24 Oncology Models Forum (Collaborative Agreement)

The purpose of this set of Funding Opportunity Announcements (FOAs) is to invite applications for projects to expand and improve the utility of mouse cancer and tumor models for translational research. The NCI supports many hypothesis-driven, mechanistic R01 projects that employ mice, or develop and use mouse cancer models or human-in-mouse tumor models for many aspects of oncology research.  However, the NCI has not previously supported projects devoted to ensuring that mice and mouse models used for translational research questions are appropriate for those purposes and that the models provide reliable and informative data for patient benefit.  Applications could propose to overcome limitations of mouse and human-in-mouse oncology models, define a new translational use of models or mouse genetics for unmet needs, advance standard practices for modeling human cancers and tumors in mice and for validating and credentialing models, or develop widely applicable tool strains or resources that enable cross-species comparisons.

Letter of Intent Due Date: Not Applicable
Application Due Date: Standard dates apply (until May 8, 2017 (except U24))


For any internal or external application:

You write the science, let the CCTS do the rest.  Contact for more information.

Tip of the Week!

Stay on top grant submission items of interest (including policy changes and research opportunities) by subscribing to important newsletters and blogs:  eRA, eSubmission,​ Extramural Nexus and Dr. R​ockey’s Rock TalkContact the CCTS Research Commons (; 4.7442) to learn more.

UAB Policy when Number of Submissions is Limited by Sponsor

Some sponsors restrict the total number of applications submitted per institution, school, and/or discipline. When the sponsor's program guidelines stipulate a limit, an internal review process may be necessary to determine the applicant(s) or proposal(s) to represent UAB.​​  Please see these guidelines​.  If you have any questions, please contact